RT Journal Article
SR Electronic
T1 Cognitive decline associated with anticholinergics, benzodiazepines, and Z-drugs: findings from The Irish Longitudinal Study on Ageing (TILDA)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.09.20095661
DO 10.1101/2020.05.09.20095661
A1 Moriarty, Frank
A1 Savva, George M
A1 Grossi, Carlota M
A1 Bennett, Kathleen
A1 Fox, Chris
A1 Maidment, Ian
A1 Loke, Yoon K
A1 Steel, Nicholas
A1 Kenny, Rose Anne
A1 Richardson, Kathryn
YR 2020
UL http://medrxiv.org/content/early/2020/05/13/2020.05.09.20095661.abstract
AB Aim To estimate the association between patterns of anticholinergic, benzodiazepine, and Z-drug medication use and change in cognitive function in middle-aged and older adults.Method This prospective cohort study used data from the first three waves of The Irish Longitudinal Study on Ageing (TILDA), including community-dwelling adults aged ≥50 years followed for up to four years (n=7,027).Cognitive function was assessed using the Mini Mental State Examination, animal naming test, and word recall tests. Regular medication use was self-reported at baseline and follow-up interviews at two and four years. Pharmacy dispensing claims for a subset (n=2,905) allowed assessment of medication use between interviews and cumulative dosage. Medication use at consecutive waves of TILDA was analysed in relation to change in cognitive function between waves.Results Strongly anticholinergic medications (Anticholinergic Cognitive Burden scale 3), benzodiazepines, and Z-drugs were reported by 7.3%, 5.8% and 5.1% of participants respectively at any time during the study. Adjusting for potential confounders, new anticholinergic use between interviews was associated with change in recall score (−1.09, 95% confidence interval −1.64, −0.53) over 2 years compared to non-use, but not with MMSE (0.07; 95%CI -0.21, 0.34) or animal naming (−0.70; −1.43, 0.03). The pharmacy claims analysis was consistent with this finding. Other hypothesised associations were not supported.Discussion Except for new use of anticholinergic medications, no other findings supported a risk of cognitive decline over 2-year periods in this middle-aged and older cohort. Patients and prescribers should weigh this potential risk against potential benefits of commencing anticholinergic medications.What is already known about this subject:Benzodiazepines, Z-drugs and drugs with anticholinergic activity have been linked with cognitive impairment.Most evidence is derived from observational studies of older people, with little research on middle-aged adults.Medication effects may be confounded by indication and these medications are often prescribed for early symptoms of prodromal stages of dementia.What this study adds:In this study of adults aged 50 years and older, no consistent pattern of change in cognitive function was associated with the medication exposures tested, except for reduced recall among new users of anticholinergic medications.Further research in the younger-old adult population should be conducted to confirm these findings.Competing Interest StatementThe authors declare that they have no competing interests, other than IM has received personal fees for guest lectures and to support travel from Astellas Pharmaceuticals; YL reports personal fees from Thame Pharmaceuticals, NC and CF have received grants and personal fees from Astellas Pharmaceuticals.Funding StatementThis work was supported by the UK Alzheimer’s Society [AS-PG-2013-017]. Funding for TILDA is provided by the Irish Government, the Atlantic Philanthropies, and Irish Life.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from TILDA, with further details on access available at https://tilda.tcd.ie/data/accessing-data/. https://tilda.tcd.ie/data/accessing-data/